Unleash the power of mStab 1 for cancer immunotherapy

It has also been shown that Stabilin-1 in type II macrophages and tumor vasculature acts as a new immunosuppressive molecule in cancer. Karikoski et al 2014 showed that Stabilin-1 supports the binding of tumor-infiltrating lymphocytes to tumor vasculature and increases the understanding of leukocyte immigration to tumors. The ability of anti-Stabilin-1 antibody treatment to attenuate tumor progression in WT mice in vivo is therapeutically relevant. Thus, Stabilin-1 may be an emerging new target for modulating immune evasion and lymphatic spread in cancer (Karikoski et al 2014).

Moreover, Dunkel et al 2018 reported that Stabilin-1 does not appear to influence antibody production by controlling B cell numbers and humoral immune responses in the spleen. Instead, the study suggests that Stabilin-1 in monocytes/macrophages controls the overall activity of B cells via the production of inflammatory cytokines.

Deletion or neutralization of Stabilin-1 enhances the antitumor immune response at least in melanoma, lymphoma and breast cancer (Karikoski et al 2014  and Riabov et al 2016). The efficacy of anti-Stabilin 1 antibodies in some experimental models has led to the development of fully human anti-Stabilin-1 antibodies that are currently being tested in clinical trials for cancer immunotherapy. Thus, the current observations suggest that interfering with Stabilin-1 function should not lead to suppression of antibody production, but may actually enhance the humoral immune response against tumor antigens (Dunkel et al 2018).

For more information see the publication  Karikoski et al 2009 and/or Manta et al 2022. Or download the product information: mStab1-1.26, InVivoPure | mStab1-1.26, InVivoPure+

InVivo is proud to be the single supplier of commercializing mStab 1-1.26 worldwide. With the launch of this novel antibody, we are proud to be part of the global effort to combat cancer and enhance diagnostic capabilities.

Together, we can make a difference in the lives of those affected by cancer! Share your thoughts or requests with us at info.invivo@bruker.com.